Richard A. Paulson - Jun 5, 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Signature
/s/Nancy Smith as Attorney-in-Fact for Richard Paulson
Stock symbol
KPTI
Transactions as of
Jun 5, 2023
Transactions value $
-$7,922
Form type
4
Date filed
6/7/2023, 04:11 PM
Previous filing
May 5, 2023
Next filing
Jul 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$7.92K -3.54K -0.44% $2.24 809K Jun 5, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $2.24 to $2.325, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.